Mikrobiomik is a biopharmaceutical company born for the research, development, production and commercialization of biologic medicines based on the human microbiome.
At Mikrobiomik we are developing a new generation of biologic medicines based on the human microbiome, focused on serious diseases, currently with no therapeutic alternative.
Our first biologic medicine under investigation, MBK-01, oriented to the treatment of intestinal infection by Clostridioides difficile, is in phase III, so we estimate its commercialization in the first part of 2024.